Masaru WakatsukiShingo KatoTatsuya OhnoParvin Akhter BanuNguyen Cong HoangErdenetuya YadamsurenNana SuprianaJianping CaoC. R.Beena DeviMiriam Joy CalaguasYaowalak ChansilpaChul Koo ChoTasbolat AdylkhanovNoriyuki OkonogiTakashi NakanoHirohiko TsujiiThe First Affiliated Hospital of Soochow UniversityJichi Medical UniversitySemey Medical UniversitySt. Luke's Medical Center Quezon CityUniversity of Indonesia, RSUPN Dr. Cipto MangunkusumoKorea Institute of Radiological and Medical SciencesSaitama Medical UniversityNational Institute of Radiological Sciences ChibaFaculty of Medicine, Siriraj Hospital, Mahidol UniversitySarawak General HospitalGunma University Faculty of MedicineDelta Hospitals LimitedNational Cancer CenterNational Cancer Hospital2020-01-272020-01-272019-09-01International Journal of Radiation Oncology Biology Physics. Vol.105, No.1 (2019), 183-1891879355X036030162-s2.0-85068438634https://repository.li.mahidol.ac.th/handle/123456789/50101© 2019 Elsevier Inc. Purpose: This multi-institutional observational study conducted among 11 countries in East and Southeast Asia aimed to assess the clinical outcomes of prophylactic extended-field concurrent chemoradiation therapy using weekly cisplatin for patients with locally advanced cervical cancer. Methods and Materials: Between October 2007 and May 2016, 106 patients with untreated squamous cell carcinoma of the cervix were enrolled in the present study. Radiation therapy consisted of pelvic irradiation (total dose, 50 Gy in 25 fractions including central shielding), prophylactic paraortic regional irradiation (36-40 Gy in 20 fractions), and either high- or low-dose-rate intracavitary brachytherapy (ICBT) according to institutional practice. The planned point A dose was 21 to 28 Gy in 3 to 4 fractions for high-dose-rate ICBT and 40 to 41 Gy in 1 to 2 fractions for low-dose-rate ICBT. Five cycles of weekly cisplatin (40 mg/m2) were administered during the radiation therapy course. Results: A total of 106 patients were enrolled. Of these, 9 had major protocol violations and 2 did not receive treatment because of worsened general condition. Thus, 95 patients were evaluable. The median follow-up was 56 months. Of the 95 patients, 76 (80%) received 4 or 5 cycles of chemotherapy. Acute grade 3 leukopenia was observed in 20 of the patients (21%), and late grade 3 gastrointestinal toxicity was observed in 3%. The 2-year local control, progression-free survival, and overall survival rate for all patients were 96%, 78%, and 90%, respectively. Conclusions: The results indicated that prophylactic extended-field concurrent chemoradiation therapy using weekly cisplatin is feasible and effective for patients with locally advanced cervical cancer in East and Southeast Asia.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyMedicineArticleSCOPUS10.1016/j.ijrobp.2019.04.039